Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients

This study investigates the effectiveness of estrogen monotherapy in suppressing testosterone levels in gender diverse individuals assigned male at birth, specifically transfeminine patients. The retrospective chart review included 10 patients aged 19-81, with 7 identifying as transfeminine. The study found that estrogen monotherapy successfully suppressed testosterone levels to below 50 ng/dL in 100% of the transfeminine patients when serum estradiol was above 100 pg/mL. Injectable estrogen formulations were most commonly associated with successful testosterone suppression. The study highlights the potential for estrogen monotherapy to simplify treatment protocols for transfeminine patients, though it acknowledges the limitation of a small sample size and the need for further research.